ProfileGDS5678 / 1456735_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 86% 84% 85% 84% 85% 87% 85% 91% 89% 85% 83% 84% 81% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.444586
GSM967853U87-EV human glioblastoma xenograft - Control 26.3055784
GSM967854U87-EV human glioblastoma xenograft - Control 36.3351685
GSM967855U87-EV human glioblastoma xenograft - Control 46.4116584
GSM967856U87-EV human glioblastoma xenograft - Control 56.4019785
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3753387
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.2574185
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2866391
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.0200689
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.4706585
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1139483
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.3077384
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7764581
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2195884